SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read More
Tag: GLP-2
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
